NewsOct 4, 2026
Yes. On October 2, 2026 the FDA approved pirtobrutinib (Jaypirca) as a first-line daily pill for adults with newly diagnosed CLL or SLL, as long as the cancer doesn't carry a 17p chromosome deletion. In the trial behind the approval, pirtobrutinib cut the risk of progression or death by about four-fifths compared with chemotherapy. A separate head-to-head found it both more effective and gentler on the heart than ibrutinib. The catch: no trial has yet tested it against the two second-generation BTK pills most oncologists reach for first.
NewsOct 4, 2026
Most of the infections behind the "1 in 8 cancers" headline are preventable or treatable. Four pathogens do almost all the damage: Helicobacter pylori, HPV, hepatitis B, and hepatitis C. For each, there's a specific move with real human evidence: a vaccine, a stool or blood test, a short course of pills. The size of the effects is unusual. Vaccinating against HPV before age 17 cuts invasive cervical cancer by around 80 to 88 percent. The useful question isn't the global percentage. It's which of the four applies to you, and whether you've acted on it.
NewsSep 27, 2026
If you get screened between 50 and 74, roughly 10 to 20% of the cancers a mammogram finds are ones that would never have hurt you. That's worth knowing, but it isn't the '1 in 3' from older studies, and it isn't under 5% either. What moves the number most is your age. Through the core screening years, biennial mammography still comes out clearly in your favor.
NewsSep 26, 2026
If you're 50 or older and worried about the cancers no one screens for, Galleri is a reasonable add-on. An FDA advisory panel just voted 7-2-1 that its benefits outweigh its risks. It's still a prescription screen you pay for out of pocket at $949, not a replacement for your mammogram, colonoscopy, or lung CT. When the test fires, it points to the right organ about 85% of the time. The catch: it misses most stage I cancers, and a positive result is more often wrong than right in healthy adults.
NewsSep 24, 2026
Probably yes, especially if you get the shot before age 27. The vaccine is proven to sharply reduce vaccine-type oral HPV infections, especially HPV-16, the type behind most HPV-positive throat cancers. Now real-world data show the cancers themselves turning up far less often in vaccinated people. That's an association, not proof. But it points the same way as everything that came before it.
NewsSep 8, 2026
If you're on a first-line aromatase inhibitor plus a CDK4/6 inhibitor for HR-positive, HER2-negative metastatic breast cancer, there's a new option worth understanding. On September 4, 2026, the FDA approved camizestrant (Etcamah) as the first cancer therapy triggered by a blood test rather than a growing tumor on a scan. In the trial that won it approval, switching the moment an ESR1 mutation appeared in the blood roughly doubled the time before the cancer advanced. Whether it also extends life is what the next few years of follow-up will answer.
CancerSep 3, 2026
A 3D mammogram is still a mammogram, but it takes X-ray images from several angles and rebuilds the breast into thin slices, so overlapping tissue is less likely to hide a cancer or mimic one. In practice it usually finds a little more cancer, especially invasive tumors, and in U.S. clinics it often means fewer callbacks for a second look. What it hasn't yet clearly proven is that catching those extra cancers leads to fewer interval cancers, advanced cancers, or breast cancer deaths for most women. If 3D is available and covered, it's a reasonable choice; if only 2D is available or affordable, the mammogram you actually get on schedule matters far more than which machine takes it.
MedicationAug 30, 2026
Yes, for most adults with polycythemia vera who depend on regular phlebotomies, a newly approved once-weekly shot can replace them. The FDA cleared Mimrylo (rusfertide) on August 28, 2026. It's an add-on to standard care, not a cure, and hasn't yet been shown to prevent clots or extend life.
CancerAug 26, 2026
Yes. In the trial that led to its August 26, 2026 approval, daraxonrasib (Rasonque) roughly doubled median survival over standard chemotherapy in adults with previously treated metastatic pancreatic cancer. It's a once-daily pill that blocks mutant RAS, the mutation driving nearly every pancreatic tumor, so most patients qualify without special testing. It's easier to stay on than chemo. Resistance still comes. And the drug is expensive.
CancerAug 22, 2026
If your high-risk melanoma has been fully removed, a personalized mRNA vaccine may help keep it from coming back. In a phase 2b trial, adding intismeran autogene (formerly mRNA-4157 or V940) to pembrolizumab led to fewer recurrences and fewer distant metastases than pembrolizumab alone. On August 19, 2026, Moderna and Merck said the larger phase 3 trial met its recurrence and distant-metastasis endpoints. But the vaccine isn't approved, and its topline release gave no effect sizes or survival data. The proven move today is still standard adjuvant care after surgery.
NutritionAug 5, 2026
Ordinary diet-soda drinking hasn't been shown to cause cancer. In 2023, IARC called aspartame "possibly carcinogenic." The same year, JECFA, another WHO-linked committee, read much of the same evidence with one difference: it asked what happens at the amounts people actually consume, and left its daily intake limit where it was. IARC's label flags a possible hazard, not a proven risk at ordinary intake. The signals behind it are limited. Some observational studies report modest cancer associations, and the animal and mechanistic evidence has big gaps. What follows is what the evidence supports, where it's shaky, and who has reason to cut back.
Vitamin B12Jun 4, 2026
Vitamin B12 is an essential nutrient responsible for maintaining healthy nerve function, producing red blood cells, and supporting DNA synthesis. When the body lacks sufficient B12, a variety of symptoms can appear, including fatigue, cognitive changes, anemia, and neurological issues. These symptoms are typically attributed to nutritional causes or absorption problems. However, research has increasingly identified links between vitamin B12 deficiency and certain cancers, raising important questions about whether such a deficiency could sometimes be a sign of an undiagnosed malignancy.
Skin HealthJun 4, 2026
The nose is the single most common site on the face for non-melanoma skin cancer. It protrudes, it catches sun year-round, and its complex anatomy makes both removal and repair a challenge. But the research is clear on what determines whether nasal skin cancer comes back: clean surgical margins. When surgeons achieve clear margins, recurrence sits around 6%. With positive (incomplete) margins, it climbs to roughly 24%.
That fourfold gap makes the surgical approach one of the most consequential decisions in treatment, sometimes more so than the specific type of cancer itself.
Prostate CancerJun 4, 2026
Eligard, an injectable form of leuprolide acetate, pushes testosterone down to castrate levels in the vast majority of men with prostate cancer. But "vast majority" ranges from 94% to 98% with shorter dosing intervals, dropping to roughly 88–90% with the longest option. That gap is worth understanding if you or someone you care about is choosing between a shot every month versus every six months.
Eligard works as a GnRH agonist (gonadotropin-releasing hormone agonist), which essentially tricks the brain's hormonal signaling system into shutting down testosterone production. It uses a polymer gel called Atrigel that forms a small biodegradable implant under the skin, slowly releasing leuprolide over weeks or months depending on the formulation.
CancerJun 4, 2026
CA 19-9 is the most validated blood marker for pancreatic cancer, yet it catches only about 72–80% of symptomatic cases and flags plenty of people who don't have cancer at all. It's a genuinely useful tool in the right context, but it's also widely misunderstood. If your doctor ordered this test, or if a result came back high (or suspiciously normal), understanding what CA 19-9 can and can't tell you matters more than the number on the page.
CancerJun 4, 2026
The clinical trial that won Cologuard FDA approval enrolled 9,989 people, each of whom collected a stool sample at home before their colonoscopy. Not one of them was told to skip red meat, avoid raw broccoli, or stop their vitamin C beforehand. The same was true in the 20,176-person trial of the next-generation version of the test.
That isn't a study oversight. It's the entire point of how Cologuard is built. The test looks for things that only come from your own gut, not from your last meal, so dietary prep would be redundant.
Blood TestsJun 4, 2026
A high albumin-to-globulin (A/G) ratio is one of those lab results that tends to cause worry for no reason. Across a wide range of conditions, from stroke to cancer to heart disease, a higher A/G ratio consistently tracks with better outcomes, not worse ones. The research is surprisingly clear on this: if your A/G ratio is going to lean in one direction, high is almost always preferable to low.
That said, "high" is relative. The clinical context, your other lab values, and just how high we're talking about all matter. There is a narrow window where a very elevated A/G ratio could signal something worth investigating, but the threshold for concern is well above what most people see on their results.
CancerJun 4, 2026
Most people learn to watch for dark, irregularly shaped moles. Amelanotic melanoma skips that playbook entirely. It shows up pink, red, or skin-colored, carrying little to no visible pigment. That disguise is the core problem: clinicians misdiagnose it anywhere from 25% to 89% of the time, and lesions often sit on the skin for more than a year before anyone identifies them correctly.
The result is predictable and grim. By the time amelanotic melanoma gets a proper diagnosis, tumors tend to be thicker, more advanced, and associated with worse survival than their pigmented counterparts. The cancer itself isn't inherently more lethal. It just gets a massive head start.
CancerJun 4, 2026
The honest answer about stage 4 lung cancer survival is that it depends enormously on specifics most people never hear about until they're sitting in an oncologist's office. Median survival still lands somewhere between 7 and 12 months for many patients treated with standard chemotherapy alone. But certain combinations of tumor biology, treatment type, and patient fitness are pushing some people well past the 5-year mark. The distance between the worst-case and best-case scenarios has never been wider.
That spread matters. It means a single "average" number is almost misleading. What actually predicts where someone falls on that spectrum is the type of lung cancer, whether it carries specific genetic mutations, how many places it has spread, overall health, and which treatments are on the table.
CancerJun 4, 2026
The next-generation version of Cologuard catches roughly 94% of colorectal cancers from a single stool sample collected on your bathroom counter. That sentence sounds like marketing copy, but it comes from a meta-analysis of 55 studies comparing the multi-target stool DNA test against colonoscopy as the reference standard.
If your doctor has handed you a kit, or you ordered one yourself, the next question is mechanical. What do you actually do with this box? Below is the full set of Cologuard instructions, what each step is checking for, and what the evidence says about how the test performs when used the way it was designed to be used.
